Android app on Google Play

Jefferies Cuts Numbers on ViroPharma (VPHM) But Says Buy on "Overreaction"

April 11, 2012 7:14 AM EDT Send to a Friend
Get Alerts VPHM Hot Sheet
Price: $49.96 --0%

Rating Summary:
    7 Buy, 13 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 24 | New: 21
Trade VPHM Now!
Join SI Premium – FREE
Jefferies cut estimates and its price target on ViroPharma (NASDAQ: VPHM) from $37 to $33 but is keeping its Buy rating after the FDA approved three generic versions of Vancocin and responded to VPHM’s citizen petition, detailing their denial of 3-year exclusivity for Vancocin.

"We would be buyers on today's overreaction, as Cinryze is the critical driver of the VPHM story," the analyst said.

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $22.44 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment